Neuralstem (CUR +0.9%) starts testing the safety of its NSI-189 treatment for Major Depressive...

|By:, SA News Editor

Neuralstem (CUR +0.9%) starts testing the safety of its NSI-189 treatment for Major Depressive Disorder on a second set of patients after receiving FDA approval to do so. "There were no surprises" in the first cohort of patients in the Phase Ib study, the company says. (PR)